Clinical Trials on Lung Neuroendocrine Tumor G1

Total 4902 results

National Cancer Institute (NCI)

Active, not recruiting

Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor

Neuroendocrine Tumor | Neuroendocrine Neoplasm | Colorectal Neuroendocrine Tumor G1 | Gastric Neuroendocrine Tumor G1 | Neuroendocrine Tumor G2

United States
National Cancer Institute (NCI)

Active, not recruiting

Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors

Metastatic Digestive System Neuroendocrine Tumor G1 | Recurrent Digestive System Neuroendocrine Tumor G1 | Regional Digestive System Neuroendocrine Tumor G1 | Metastatic Neuroendocrine Tumor | Midgut Neuroendocrine Tumor G1 | Foregut Neuroendocrine Tumor | Hindgut Neuroendocrine Tumor | Neuroendocrine...

Canada, United States
National Cancer Institute (NCI)

Recruiting

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

Locally Advanced Lung Neuroendocrine Neoplasm | Lung Neuroendocrine Neoplasm | Metastatic Lung Neuroendocrine Neoplasm | Recurrent Lung Neuroendocrine Neoplasm | Unresectable Lung Neuroendocrine Neoplasm | Advanced Lung Neuroendocrine Tumor | Functioning Lung Neuroendocrine Tumor | Lung Neuroendocrine... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

Carcinoid Tumor | Functioning Pancreatic Neuroendocrine Tumor | Intermediate Grade Lung Neuroendocrine Neoplasm | Locally Advanced Pancreatic Neuroendocrine Tumor | Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm | Low Grade Lung Neuroendocrine Neoplasm | Metastatic Digestive... and other conditions

United States
National Cancer Institute (NCI)

Recruiting

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus Everolimus in Patients With Metastatic Unresectable Midgut Neuroendocrine Tumors, NET RETREAT Trial

Metastatic Midgut Neuroendocrine Tumor | Unresectable Midgut Neuroendocrine Tumor | Metastatic Midgut Neuroendocrine Tumor G1 | Metastatic Midgut Neuroendocrine Tumor G2

United States, Canada
Vanderbilt-Ingram Cancer Center

Recruiting

Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors

Metastatic Digestive System Neuroendocrine Neoplasm | Metastatic Malignant Neoplasm in the Liver | Pancreatic Neuroendocrine Tumor G1 | Pancreatic Neuroendocrine Tumor G2 | Digestive System Neuroendocrine Tumor G1 | Digestive System Neuroendocrine Tumor G2

United States
National Cancer Institute (NCI)

Completed

Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer

Lung Carcinoid Tumor | Metastatic Digestive System Neuroendocrine Tumor G1 | Pancreatic Polypeptide Tumor | Multiple Endocrine Neoplasia Type 1 | Pancreatic Glucagonoma | Pancreatic Insulinoma | Somatostatin-Producing Neuroendocrine Tumor | Recurrent Digestive System Neuroendocrine Tumor G1 | Recurrent... and other conditions

United States
National Cancer Institute (NCI)

Completed

Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma

Lung Carcinoid Tumor | Metastatic Digestive System Neuroendocrine Tumor G1 | Paraganglioma | Pancreatic Polypeptide Tumor | Pancreatic Glucagonoma | Pancreatic Insulinoma | Recurrent Merkel Cell Carcinoma | Somatostatin-Producing Neuroendocrine Tumor | Stage IV Merkel Cell Carcinoma | Recurrent Digestive... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Novartis

Completed

Ribociclib in Treating Patients With Advanced Neuroendocrine Tumors of Foregut Origin

Intermediate Grade Lung Neuroendocrine Neoplasm | Low Grade Lung Neuroendocrine Neoplasm | Functional Pancreatic Neuroendocrine Tumor | Advanced Digestive System Neuroendocrine Neoplasm | Duodenal Neuroendocrine Tumor G1 | Gastric Neuroendocrine Tumor | Nonfunctional Pancreatic Neuroendocrine... and other conditions

United States
National Cancer Institute (NCI)

Completed

Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery

Locally Advanced Pancreatic Neuroendocrine Tumor | Pancreatic Neuroendocrine Tumor G1 | Pancreatic Neuroendocrine Tumor G2 | Pancreatic Vipoma | Pancreatic Gastrinoma | Advanced Pancreatic Neuroendocrine Tumor

United States, Canada
M.D. Anderson Cancer Center

Recruiting

An Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid Tumors

Carcinoid Tumor | Carcinoid Syndrome | Metastatic Carcinoid Tumor | Digestive System Neuroendocrine Tumor G1

United States
National Cancer Institute (NCI)

Completed

Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery

Refractory Pancreatic Neuroendocrine Carcinoma | Pancreatic Neuroendocrine Tumor G1 | Pancreatic Neuroendocrine Tumor G2

United States
Roswell Park Cancer Institute
NeuroEndocrine Tumor Research Foundation (NETRF)

Recruiting

Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors

Lung Atypical Carcinoid Tumor | Metastatic Pancreatic Neuroendocrine Tumor | Lung Typical Carcinoid Tumor

United States
TaiRx, Inc.

Active, not recruiting

Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors

Neuroendocrine Tumors | Gastro-enteropancreatic Neuroendocrine Tumor | Neuroendocrine Carcinoma | Pancreatic Neuroendocrine Tumor | Lung Neuroendocrine Neoplasm

Taiwan
David Bushnell
National Cancer Institute (NCI); Holden Comprehensive Cancer Center; Perspective...

Active, not recruiting

A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors

Neuroendocrine Tumors | Neuroendocrine Tumor of the Lung | Neuroendocrine Tumor Grade 2 | Neuroendocrine Tumor Grade 1 | Neuroendocrine Tumor of Pancreas

United States
National Cancer Institute, Naples

Recruiting

A Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT (CABOTEM) (CABOTEM)

Lung Neuroendocrine Neoplasm | GEP Neuroendocrine Tumor

Italy
Perspective Therapeutics

Recruiting

Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors (212-Pb-VMT)

Neuroendocrine Tumors | Pheochromocytoma | Carcinoid Tumor | Paraganglioma | Neuroendocrine Tumor of the Lung | Neuroendocrine Carcinoma Metastatic | Neuroendocrine Tumor of Pancreas | Neuroendocrine Tumor Carcinoid | Carcinoid Tumor of GI System

United States
Dana-Farber Cancer Institute
Bayer; Novartis

Completed

Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors

Neuroendocrine Tumor | Carcinoid Tumor | Pancreatic Neuroendocrine Tumor

United States
Dana-Farber Cancer Institute
Massachusetts General Hospital; Novartis; Beth Israel Deaconess Medical Center; Brigham and Women's Hospital

Completed

Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors

Neuroendocrine Tumor | Carcinoid Tumor | Pancreatic Neuroendocrine Tumor

United States
Advanced Accelerator Applications

Completed

A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours (NETTER-1)

Carcinoid Tumor of the Small Bowel | Neuroendocrine Tumour

United States, United Kingdom, Italy, Belgium, France, Germany, Portugal, Spain
Vanquish Oncology, Inc.
University of Illinois at Chicago

Completed

Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1

Solid Tumor | Neuroendocrine Tumors | Pancreatic Neuroendocrine Tumor

United States
University of Iowa
Patient-Centered Outcomes Research Institute; Medical University of South Carolina and other collaborators

Enrolling by invitation

Neuroendocrine Tumors - Patient Reported Outcomes (NET-PRO)

Neuroendocrine Tumors | Neuroendocrine Carcinoma | Lung Neuroendocrine Neoplasm | Gastroenteropancreatic Neuroendocrine Tumor

United States
H. Lee Moffitt Cancer Center and Research Institute

Completed

Clinical Utility Assay as a Biomarker for Gastroenteropancreatic and Lung Neuroendocrine Tumors

Lung Neuroendocrine Neoplasm | Gastroenteropancreatic Neuroendocrine Tumor

United States
National Cancer Institute (NCI)

Not yet recruiting

A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

Carcinoma, Neuroendocrine | Tumor, Neuroendocrine | Tumors, Neuroendocrine | Neuroendocrine; Carcinoma | Small Cell; Receptors

United States
David Bushnell
National Cancer Institute (NCI); National Institutes of Health (NIH); Holden...

Active, not recruiting

Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine Tumors

Neuroendocrine Tumor Gastrointestinal, Hormone-Secreting | Neuroendocrine Tumor, Malignant

United States
Yusuf Menda
National Cancer Institute (NCI); Holden Comprehensive Cancer Center; Perspective...

Enrolling by invitation

A First-in-human Clinical Trial to Evaluate an Alpha-radiation Imaging Agent

Neuroendocrine Tumor Grade 2 | Neuroendocrine Tumor Grade 1

United States
University of Iowa
Novartis

Not yet recruiting

177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry (LUMOD-ID)

Neuroendocrine Tumors | Neuroendocrine Tumor Grade 2 | Neuroendocrine Tumor Grade 1

United States
University of Roma La Sapienza

Recruiting

Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN) (REBORN)

Neuroendocrine Tumors | Neuroendocrine Carcinoma | Neuroendocrine Neoplasm | Neuroendocrine Tumor Grade 2 | Neuroendocrine Tumor Grade 1

Italy
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.

Advanced Gastroenteropancreatic Neuroendocrine Tumor

China
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

Gallium (68Ga) Edotreotide PET/CT for Imaging Patients With Gastrointestinal Pancreatic Neuroendocrine Tumors

Advanced Gastroenteropancreatic Neuroendocrine Tumor
Francesco De Cobelli

Completed

CT Radiomic Features of Pancreatic Neuroendocrine Neoplasms

Pancreatic Neuroendocrine Tumor

Italy
Grupo Espanol de Tumores Neuroendocrinos

Active, not recruiting

Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.

Neuroendocrine Tumors | Neuroendocrine Neoplasm | Gastroenteropancreatic Neuroendocrine Tumor

Spain
Peter Anderson

Completed

Phase 2 Study of ONC201 in Neuroendocrine Tumors

Metastatic Neuroendocrine Tumor | Recurrent Neuroendocrine Tumor

United States
Dana-Farber Cancer Institute

Completed

Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

Carcinoid Tumor | Pancreatic Neuroendocrine Tumor

United States
University of Washington
Eli Lilly and Company

Recruiting

Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors

Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm | Metastatic Digestive System Neuroendocrine Neoplasm | Pancreatic Neuroendocrine Tumor | Advanced Digestive System Neuroendocrine Neoplasm | Digestive System Neuroendocrine Tumor | Foregut Neuroendocrine Tumor | Hindgut Neuroendocrine... and other conditions

United States
Vyriad, Inc.
Mayo Clinic

Recruiting

Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors

Solid Tumor | Non Small Cell Lung Cancer | Neuroendocrine Carcinoma

United States
Ipsen

Completed

To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)

Gastro-Enteropancreatic Neuroendocrine Tumor

United States, Austria, Denmark
Amr Mohamed MD
Novatek Pharmaceuticals

Active, not recruiting

NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas

Neuroendocrine Carcinoma | Gastroenteropancreatic Neuroendocrine Tumor | Gastroenteropancreatic Neuroendocrine Neoplasm | Mixed Neuroendocrine-Non Neuroendocrine Neoplasm

United States
National Cancer Institute (NCI)

Completed

Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Recurrent Uterine Corpus Sarcoma | Recurrent Renal Cell Carcinoma | Stage III Renal Cell Cancer | Lung Carcinoid Tumor | Stage IV Renal Cell Cancer | Recurrent Digestive System Neuroendocrine Tumor G1 | Adult Solid Neoplasm | Stage IIIB Uterine Sarcoma | Stage IIIC Uterine Sarcoma | Stage IVA Uterine Sarcoma and other conditions

Canada
Maastricht University Medical Center

Unknown

Everolimus TDM to Predict Long Term Toxicity (Foresight)

Renal Cell Carcinoma | Breast Cancer | Neuroendocrine Neoplasm of Lung | Pancreatic Neuroendocrine Tumour | Gastrointestinal Neuroendocrine Tumour

Netherlands
Hutchmed

Active, not recruiting

Open-Label Surufatinib in European Patients With NET

Neuroendocrine Tumours | Neuroendocrine Tumour of the Lung | Small Intestinal NET

Spain, France, United States, United Kingdom, Norway, Germany, Italy
Yusuf Menda
National Cancer Institute (NCI); National Institutes of Health (NIH); Holden...

Not yet recruiting

A Safety Study of 212Pb-Pentixather Radioligand Therapy

Carcinoid Tumor Lung | Neuroendocrine Tumor of the Lung | Carcinoma, Small-Cell Lung

United States
University Hospital, Basel, Switzerland
University Hospital, Zürich; University Hospital Freiburg; Krebsforschung Schweiz... and other collaborators

Recruiting

177Lu-PP-F11N for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer. (Lumed)

Thyroid Cancer, Medullary | Neuroendocrine Tumor of the Lung Grade 1 and 2 | Neuroendocrine Tumor of the Thymus Grade 1 and 2 | Neuroendocrine Tumor GEP Grade 1-3

Switzerland
University Hospital, Antwerp
Erasmus Medical Center; ZonMw: The Netherlands Organisation for Health Research... and other collaborators

Recruiting

Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients (SAUNA)

Gastroenteropancreatic Neuroendocrine Tumor

Netherlands, Belgium
Centre Hospitalier Universitaire, Amiens

Completed

GLUT1: A Novel Tool re fl Ecting Proliferative Activity of Lung Neuroendocrine Tumors (GLUT1)

Lung Tumor
Sichuan Huiyang Life Science and Technology Corporation
Medelis Inc.

Active, not recruiting

Study of rSIFN-co for Patients With Advanced Solid Tumors

Malignancies Including Melanoma, Kidney, Lung, Colorectal, Prostate, Neuroendocrine Tumor

United States
University Medical Center Groningen

Completed

Web-based Tailored Information and Support for Patients With a Neuroendocrine Tumor (WIN)

Neuroendocrine Tumor

Netherlands
Thomas Hope

Completed

Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumor

Neuroendocrine Tumor

United States
Samsung Medical Center

Completed

Study of Pazopanib Monotherapy in Patients With Unresectable, Metastatic Neuroendocrine Tumor

Neuroendocrine Tumor

Korea, Republic of
Nuclear Medicine Consultants, Inc.

Unknown

Heart/Mediastinal Ratio Study for Potential Equivalence of Heart/Mediastinal Ratios at One and Two Hours to the Traditional Heart/Mediastinal Ratio Obtained at Four Hours

Neuroendocrine Tumor

United States

Clinical Trials on Lung Neuroendocrine Tumor G1

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tanzania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations